Table 2 Clinical parameters of included participants.
Variables | HT group (n = 108) | Control group (n = 57) | P value |
---|---|---|---|
TSH, mIU/L | 2.55 (1.78, 3.73) | 2.19 (1.63, 3.96) | 0.283 |
FT3, pmol/L | 4.28 ± 0.47 | 4.35 ± 0.44 | 0.513 |
FT4, pmol/L | 14.94 ± 2.59 | 15.28 ± 2.01 | 0.366 |
TPO-Ab, KU/L | 178.25 (15.38, 530.62) | 0.37 (0.26, 0.48) |  < 0.001 |
TG-Ab, KU/L | 28.49 (2.72, 205.53) | 0.26 (0.20, 0.28) |  < 0.001 |
TC, mmol/L | 4.86 ± 0.83 | 4.45 ± 0.82 | 0.029 |
TG, mmol/L | 0.96 ± 0.50 | 0.90 ± 0.36 | 0.556 |
LDL-C, mmol/L | 2.83 ± 0.71 | 2.37 ± 0.60 | 0.003 |
HDL-C, mmol/L | 1.62 ± 0.39 | 1.37 ± 0.28 | 0.003 |
CD3+/total lym, % | 70.81 ± 7.16 | 72.53 ± 6.69 | 0.278 |
CD4+/total lym, % | 35.37 ± 6.70 | 36.63 ± 5.66 | 0.381 |
CD8+/total lym, % | 28.61 ± 7.02 | 30.43 ± 5.41 | 0.219 |
CD4+/CD8+ | 1.34 ± 0.53 | 1.25 ± 0.34 | 0.411 |
IL-4, pg/mL | 0.46 ± 0.30 | 0.68 ± 0.73 | 0.043 |
IL-6, pg/mL | 1.40 ± 0.91 | 1.73 ± 1.19 | 0.147 |
IL-10, pg/mL | 1.69 ± 0.84 | 1.76 ± 1.02 | 0.719 |
TNF-α, pg/mL | 1.25 ± 0.63 | 0.84 ± 0.73 | 0.008 |
IFN-γ, pg/mL | 2.08 ± 0.53 | 0.77 ± 0.73 |  < 0.001 |
IgG, g/L | 12.99 ± 2.29 | 12.82 ± 1.93 | 0.723 |
IgM, g/L | 1.22 ± 0.42 | 1.30 ± 0.37 | 0.418 |
IgA, g/L | 1.85 ± 0.68 | 1.80 ± 0.61 | 0.737 |
ALT, U/L | 19.30 ± 18.46 | 15.52 ± 5.81 | 0.286 |
AST, U/L | 24.09 ± 10.71 | 17.13 ± 3.83 |  < 0.001 |
TP, g/L | 74.99 ± 4.79 | 72.99 ± 3.07 | 0.041 |
ALB, g/L | 46.62 ± 2.67 | 45.09 ± 1.91 | 0.007 |
GLOB, g/L | 28.37 ± 3.98 | 27.90 ± 2.29 | 0.545 |
hsCRP, mg/L | 0.57 (0.42, 1.03) | 0.20 (0.10, 0.54) |  < 0.001 |